Paloma Partners Management CO Exelixis, Inc. Transaction History

Paloma Partners Management CO

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$21.96 - $27.6 $409,224 - $514,326	18,635 New	18,635 $483,000
Q1 2024 May 15, 2024	BUY	$20.17 - $23.93 $276,571 - $328,128	13,712 New	13,712 $325,000
Q3 2021 Nov 15, 2021	SELL	$16.3 - $21.14 $1.05 Million - $1.37 Million	-64,581 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$17.95 - $25.56 $1.16 Million - $1.65 Million	64,581 New	64,581 $1.18 Million
Q3 2020 Nov 16, 2020	SELL	$20.67 - $26.94 $2.36 Million - $3.08 Million	-114,251 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$16.46 - $27.42 $1.88 Million - $3.13 Million	114,251 New	114,251 $2.71 Million
Q4 2019 Feb 14, 2020	SELL	$15.15 - $18.89 $379,113 - $472,703	-25,024 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$17.68 - $22.65 $592,633 - $759,228	-33,520 Reduced 57.26%	25,024 $442,000
Q2 2019 Aug 14, 2019	SELL	$18.93 - $24.75 $1.37 Million - $1.79 Million	-72,372 Reduced 55.28%	58,544 $1.25 Million
Q1 2019 May 15, 2019	BUY	$19.6 - $24.76 $1.59 Million - $2 Million	80,972 Added 162.13%	130,916 $3.12 Million
Q4 2018 Feb 14, 2019	BUY	$13.65 - $21.8 $399,180 - $637,519	29,244 Added 141.28%	49,944 $982,000
Q3 2018 Nov 14, 2018	BUY	$15.87 - $22.4 $328,509 - $463,679	20,700 New	20,700 $367,000
Q2 2018 Aug 14, 2018	SELL	$18.56 - $22.45 $457,819 - $553,774	-24,667 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$22.15 - $31.89 $305,227 - $439,444	13,780 Added 126.57%	24,667 $546,000
Q4 2017 Feb 14, 2018	BUY	$24.23 - $30.93 $263,792 - $336,734	10,887	10,887 $330,000

566

251M

1.45M

1.13M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.7B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Paloma Partners Management CO, based on Form 13F filings with the SEC.

Stay updated on Paloma Partners Management CO with notifications on news.